Metformin and reduced risk of cancer in diabetic patients
Explore this paper's citation graph
Summary
It is hypothesised that metformin use in patients with type 2 diabetes may reduce their risk of cancer and tested this hypothesis using record linkage databases developed in Tayside, Scotland: a diabetes clinical information system (DARTS) and a database of dispensed prescriptions (MEMO).
- Type
- article
- Published
- 2005-04-22
- Cited by
- 2,416
- References
- 8
- Access
- Open access
- OpenAlex
- https://openalex.org/W2026967508
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:35920733
Keywords
Metformin, Medicine, Cancer, Diabetes mellitus, Internal medicine
References
- The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register
- Topical non-steroidal anti-inflammatory drugs.
- LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
- Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade
- Faculty Opinions recommendation of Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.
Cited by
- Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
- Beeinflussen Diabetestherapien das Krebsrisiko?
- AMP-activated protein kinase--the fat controller of the energy railroad.
- Insulin, insulin-like growth factors, insulin resistance, and neoplasia.
- Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes
- Regulation of metformin response by breast cancer associated gene 2.
- Metformin: Its emerging role in oncology
- Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
- Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
- Prevention of ER-negative breast cancer: where do we stand?
- Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects
- Metformin selectively affects human glioblastoma tumor-initiating cell viability
- Decreased risk of liver cancer with thiazolidinediones therapy in patients with type 2 diabetes: Results from a meta‐analysis
- Hypoxia and metastasis in breast cancer.
- Association of diabetes mellitus and metformin use with oncological outcomes of patients with non‐muscle‐invasive bladder cancer
- Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
- New perspectives in ovarian cancer treatment.
- Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells
- Immune-mediated antitumor effect by type 2 diabetes drug, metformin
- Obesity and cancer, a case for insulin signaling
Related papers
- Metformin for Prevention of Type 2 Diabetes
- A Rare Side Effect of Metformin: Metformin-Induced Hepatotoxicity
- Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
- Advances in the study on metformin beyond its hypoglycemic effect
- General Study on Metformin
- P-54 : 중환자실 입실 전 투여된 metformin 이 급성 호흡곤란 증후군 환자의 예후에 미치는 영향
- Metformin and metabolic diseases： a focus on hepatic aspects
- Therapeutic and Adverse Effects of Metformin in Diabetes: A Review Article
- 359 MORTALITY RATES IN METFORMIN USERS VERSUS NON-METFORMIN USERS IN VETERANS WITH TYPE 2 DIABETES MELLITUS.